Incorporating genetic testing and counseling for prostate cancer into clinical practice

This is the largest prostate cancer study that examined the exome, according to the researchers, who believe their findings can potentially inform the makeup of panels used for genetic testing in prostate cancer.

Data showed that the proportion of Black patients referred for genomic testing increased from 19% to 58% after the implementation of the precision medicine navigator.

The findings suggest that drug therapies targeting the NOTCH1 gene may serve as an alternative treatment option for patients with kidney cancer in whom surgery is not recommended.

Approximately half of prostate cancer patients with clinically actionable gene variants do not meet the NCCN guideline criteria for genetic testing, according to findings from the PROCLAIM trial.

The study assessed US veterans receiving care at the Veterans Health Administration for all cancer types, including prostate cancer.

Patients classified as GC high risk had a 5-year disease progression of 40%, compared with 20% among GC low-risk patients.